Latest Regulatory News

Paladin Energy reports a 17% rise in quarterly uranium production and US$61 million in revenue, while recognizing a US$19.9 million inventory impairment. The company maintains strong liquidity and advances key projects in Namibia and Canada.

Patriot Battery Metals has announced a substantial upgrade to its Shaakichiuwaanaan Lithium Project, solidifying its position as the largest lithium pegmatite resource in the Americas and advancing its feasibility study on track for Q3 2025.

West African Resources has commenced mining and crushing at its Kiaka Gold Project in Burkina Faso, maintaining its schedule and budget for first gold production in the third quarter of 2025. The project’s progress signals a significant boost to the company’s annual gold output.

Humm Group reported a solid 10% increase in assets under management to $5.3 billion for 3Q25, maintaining stable margins while advancing a new hybrid loan product and IT platform modernization.

Holista Colltech Limited has responded to an ASX price query regarding recent unusual trading activity, confirming no undisclosed material information exists to explain the surge.

Raptis Group Limited has voluntarily suspended trading on the ASX as it prepares to announce a significant share placement and entitlement offer, signaling a pivotal moment for the company’s capital structure.

PolyNovo has secured Therapeutic Goods Administration clearance for thicker versions of its NovoSorb MTX product, broadening treatment options for complex wounds in Australia.

Ainsworth Game Technology's Independent Board Committee reaffirms its recommendation for shareholders to support the proposed Scheme, responding to recent media commentary from a major shareholder.

Botanix Pharmaceuticals has clarified that recent share price movements are linked to a rumored US executive order on drug pricing, confirming no undisclosed material information. The company reassures investors of compliance with ASX disclosure rules amid market speculation.

Botanix Pharmaceuticals clarifies its lead product Sofdra is unlikely to face price cuts under the proposed US executive order on drug pricing, citing its exclusive US market approval and distinct formulations abroad.

Bio-Gene Technology Limited has launched a Share Purchase Plan allowing Australian shareholders to invest up to $15,000 at 2.3 cents per share, matching a recent $2.1 million placement. The offer includes free-attaching options, subject to shareholder approval, to support key product development milestones.

Trading in Black Rock Mining Limited shares has resumed following the lifting of a suspension tied to regulatory correspondence from Tanzania about its Mahenge Graphite Project licence.